3B Blackbio DX Ltd

3B Blackbio DX Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 23 March 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price declining by 4.8% on 18 June 2026 to ₹1,204.05 from the previous close of ₹1,264.80.

3B Blackbio DX Ltd, a micro-cap player in the Healthcare Services sector, has recently experienced a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a notable 4.00% gain on 11 Jun 2026, the stock’s technical indicators present a complex picture, reflecting mixed signals across various timeframes and metrics.

3B Blackbio DX Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 09 June 2026, providing investors with the latest insights into its performance and outlook.

3B Blackbio DX Ltd’s stock price declined to a fresh 52-week low of Rs.1083.5 on 2 June 2026, marking a significant downturn for the healthcare services company amid broader market weakness and company-specific performance factors.

A sharp decline in 3B Blackbio DX Ltd shares has pushed the stock to a fresh 52-week low of Rs 1090 on 1 Jun 2026, marking a significant 12.38% intraday drop amid heightened volatility. This fall comes despite recent quarterly profit growth, underscoring a complex interplay of valuation concerns and market sentiment weighing on the micro-cap healthcare services company.

3B Blackbio DX Ltd., a micro-cap healthcare services company with a market capitalisation of ₹1,064.00 crores, posted a sharp 56.01% quarter-on-quarter decline in consolidated net profit to ₹9.56 crores in Q4 FY26, despite reporting a robust 57.47% year-on-year revenue growth to ₹35.43 crores. The disappointing bottom-line performance was primarily driven by a dramatic surge in employee costs and a significant spike in depreciation expenses, which more than offset the company's top-line expansion.

3B Blackbio DX Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with the latest insights into its performance and outlook.

3B Blackbio DX Ltd, a micro-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The stock’s recent downgrade from Hold to Sell by MarketsMOJO, accompanied by a 4.77% drop in daily price, reflects growing investor caution amid weakening price action and mixed technical signals.

3B Blackbio DX Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

3B Blackbio DX Ltd, a micro-cap player in the Healthcare Services sector, has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. The company’s current price of ₹1,250.40 reflects a 3.41% decline from the previous close, underscoring growing investor caution amid deteriorating technical signals and a downgrade in its Mojo Grade from Hold to Sell.

3B Blackbio DX Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

3B Blackbio DX Ltd, a micro-cap player in the healthcare services sector, has recently exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook. Despite a 2.88% gain on 7 May 2026, the stock’s technical indicators present a complex picture, reflecting both cautious optimism and lingering downside risks.

3B Blackbio DX Ltd is rated Sell by MarketsMOJO. This rating was last updated on 23 March 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 26 April 2026, providing investors with the latest perspective on the company’s position.

3B Blackbio DX Ltd is rated Sell by MarketsMOJO. This rating was last updated on 23 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with the latest insights into the company’s performance and outlook.

3B Blackbio DX Ltd, a micro-cap player in the healthcare services sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more pronounced bearish trend. This change is reflected across multiple technical indicators including MACD, RSI, moving averages, and Bollinger Bands, signalling increased selling pressure and subdued investor sentiment as the stock price continues to struggle below key resistance levels.

3B Blackbio DX Ltd, a micro-cap player in the Healthcare Services sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential deterioration in the stock’s trend and raises concerns about sustained weakness in the near to medium term.